17 results
8-K
EX-99.1
ALGS
Aligos Therapeutics Inc
23 Mar 21
Aligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
4:05pm
Accounting Officer at Global Blood Therapeutics, Inc.
Awarded €1.8 million Flemish Agency for Innovation and Entrepreneurship (VLAIO) grant
S-1/A
EX-10.4
ALGS
Aligos Therapeutics Inc
9 Oct 20
IPO registration (amended)
5:26pm
Preferred Stock, par value $0.0001 per share.
1.37 “Wellington” means Wellington Biomedical Innovation Master Investors (Cayman) I L.P. and its permitted … .
INVESTORS:
WELLINGTON BIOMEDICAL
INNOVATION MASTER INVESTORS
(CAYMAN) I L.P.
By: Wellington Management Company LLP, as investment adviser
By:
/s/ Peter N
DEF 14A
ALGS
Aligos Therapeutics Inc
27 Apr 21
Definitive proxy
4:15pm
member thereof:
Name
Number of
shares of
Series B-2
convertible
preferred stock
Total
purchase
price ($)
Wellington Biomedical Innovation Master … )
Julian Symons, D.Phil.(9)
Trust affiliated with Lucinda Quan, J.D.(10)
Wellington Biomedical Innovation Master Investors (Cayman) I L.P
424B4
ALGS
Aligos Therapeutics Inc
19 Oct 20
Prospectus supplement with pricing info
5:21pm
and continuing technological innovation as well as our active third-party intellectual property in-licensing program to develop and maintain our proprietary … Administration Safety and Innovation Act amended the FDCA to require that a sponsor who is planning to submit an NDA for a drug that includes a new
S-1/A
ALGS
Aligos Therapeutics Inc
9 Oct 20
IPO registration (amended)
5:26pm
innovation as well as our active third-party intellectual property in-licensing program to develop and maintain our proprietary positions … and Innovation Act amended the FDCA to require that a sponsor who is planning to submit an NDA for a drug that includes a new active ingredient, new
S-1
2uc 8ccy59hgc724mj8
25 Sep 20
IPO registration
5:27pm
DRS
dm9rzs8 u59nf
26 Aug 20
Draft registration statement
12:00am
10-K
8hhdyj21
23 Mar 21
Annual report
4:26pm
- Prev
- 1
- Next